Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Challenges and opportunities in designing clinical trials for neuromyelitis optica.
What Do Effective Treatments for Multiple Sclerosis Tell Us about the Molecular Mechanisms Involved in Pathogenesis?
The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced protein oxidation products and total thiol content in sera and csf.
Annexin A1 and the regulation of innate and adaptive immunity.
Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.
The Outlook for Alemtuzumab in Multiple Sclerosis.
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis.
[Is it always useful to perform lumbar puncture for the diagnosis of multiple sclerosis? Comment].
Purinergic mechanisms in neuroinflammation: An update from molecules to behavior.
Myeloid cell distribution and activity in multiple sclerosis.
Profilometry: A new statistical framework for the characterization of white matter pathways, with application to multiple sclerosis.
Treatment with tanshinone IIA suppresses disruption of the blood-brain barrier and reduces expression of adhesion molecules and chemokines in experimental autoimmune encephalomyelitis.
Use of Cannabinoids for Spasticity and Pain Management in MS.
Systematic review of correlates and determinants of physical activity in persons with multiple sclerosis.
Notes on the epidemiology of multiple sclerosis, with special reference to dietary habits.
Lipocalin-2 deficiency ameliorates experimental autoimmune encephalomyelitis: the pathogenic role of lipocalin-2 in the central nervous system and peripheral lymphoid tissues.
Regulatory T cell number in multiple sclerosis patients: A meta-analysis.
Evaluation of the Persian version of modified fatigue impact scale in Iranian patients with multiple sclerosis.
Review of Clinical Applications of Scalp Acupuncture for Paralysis: An Excerpt From Chinese Scalp Acupuncture.
Crohn's disease: Is there a place for neurological screening?
Natural antisense RNAs are involved in the regulation of CD45 expression in autoimmune diseases.
Including a subject-paced trial may make the PASAT more acceptable for MS patients.
Respiratory dysfunction in multiple sclerosis.
Intrinsic third ventricular craniopharyngioma: A case report.
Systematic Review and meta-analysis of the Efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in Animal Models of Stroke.
Pages
« first
‹ previous
…
582
583
584
585
586
587
588
589
590
…
next ›
last »